PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to wipe out melanoma before surgery
Disease control OngoingThis study tests whether giving drug combinations before surgery can help people with high-risk stage III melanoma. The trial involves 59 participants receiving either targeted cancer drugs, immunotherapy drugs, or both for several weeks before their operation. Researchers want t…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Balancing act: fighting cancer while protecting a transplanted kidney
Disease control OngoingThis early-phase study is testing a combination of immunotherapy drugs (nivolumab and ipilimumab) along with standard transplant medications (tacrolimus and prednisone) in kidney transplant patients with advanced skin cancers that have spread or cannot be removed by surgery. The …
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Boosting the immune system to fight skin cancer before surgery
Disease control OngoingThis study is testing if a new drug combination works better than a standard drug alone to shrink melanoma tumors before surgery. It involves 60 adults with stage III melanoma that can be surgically removed. The goal is to see if the combination helps the immune system attack the…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Scientists test 'Living Drug' to fight advanced skin cancer
Disease control OngoingThis early-stage study is testing a two-part treatment for advanced melanoma that has spread. Doctors take a patient's own immune cells from a tumor, grow them in a lab, and then infuse them back, combined with an immunotherapy drug (pembrolizumab). The goal is to see if this app…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Richard Wu • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Trial aims to cut cancer treatment time in half using scans
Disease control OngoingThis study is testing if doctors can safely stop a standard immunotherapy treatment early for people with advanced melanoma. It uses special PET scans and sometimes a biopsy taken after one year of treatment to check if the cancer is under control. If the scan and biopsy show no …
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC
-
New cancer combo aims to supercharge immune system while taming side effects
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Facebook groups fight skin cancer in families
Prevention OngoingThis study is testing whether private Facebook groups can help young melanoma survivors and their close family members prevent future skin cancer. Researchers are comparing two types of groups: one focused on skin cancer education and one on general healthy living. The goal is to…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Prevention
Last updated Mar 30, 2026 14:34 UTC
-
Tracking the hidden toll: study maps immunotherapy side effects in cancer survivors
Knowledge-focused OngoingThis study observes melanoma survivors who have completed surgery and are receiving immunotherapy drugs to prevent cancer return. Researchers follow 126 patients for two years to track side effects, symptoms like fatigue and depression, and quality of life. The goal is to underst…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:01 UTC